Gains May Be On The Menu For Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 294.42M common shares owned by the public and among those 264.11M shares have been available to trade. The company’s stock has a 5-day price change of -0.90% and -23.61% over the past three months. PACB shares are trading -39.89% year to date (YTD), with the 12-month market performance down to -37.50% lower. […]
Pacific Biosciences of California Inc (PACB): A Great Stock For Handling Current Market Conditions?
Currently, there are 294.42M common shares owned by the public and among those 262.18M shares have been available to trade. The company’s stock has a 5-day price change of -0.88% and -32.34% over the past three months. PACB shares are trading -38.25% year to date (YTD), with the 12-month market performance down to -16.91% lower. […]
Reassessing The Changing Outlook For Pacific Biosciences of California Inc (PACB)
Currently, there are 294.42M common shares owned by the public and among those 262.18M shares have been available to trade. The company’s stock has a 5-day price change of -11.36% and -31.18% over the past three months. PACB shares are trading -36.07% year to date (YTD), with the 12-month market performance down to -19.86% lower. […]
Handle With Care: Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 294.42M common shares owned by the public and among those 262.18M shares have been available to trade. The company’s stock has a 5-day price change of 5.83% and -31.35% over the past three months. PACB shares are trading -30.60% year to date (YTD), with the 12-month market performance down to -59.94% lower. […]
Is Pacific Biosciences of California Inc (NASDAQ: PACB) Back In The Buying Zone?
Currently, there are 294.42M common shares owned by the public and among those 262.18M shares have been available to trade. The company’s stock has a 5-day price change of 11.86% and -33.67% over the past three months. PACB shares are trading -27.87% year to date (YTD), with the 12-month market performance down to -60.36% lower. […]
Look At Analyst Expectations For A Better Read On Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 294.42M common shares owned by the public and among those 263.27M shares have been available to trade. The company’s stock has a 5-day price change of -11.28% and -38.86% over the past three months. PACB shares are trading -35.52% year to date (YTD), with the 12-month market performance down to -68.28% lower. […]
Pacific Biosciences of California Inc (PACB): Insights At A Glance
Pacific Biosciences of California Inc (PACB) concluded trading on Wednesday at a closing price of $1.27, with 6.26 million shares of worth about $7.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.01% during that period and on March 26, 2025 the price […]
Handle With Care: Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 273.86M common shares owned by the public and among those 243.53M shares have been available to trade. The company’s stock has a 5-day price change of -10.79% and -45.37% over the past three months. PACB shares are trading -32.24% year to date (YTD), with the 12-month market performance down to -70.75% lower. […]
Gains May Be On The Menu For Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 273.86M common shares owned by the public and among those 243.53M shares have been available to trade. The company’s stock has a 5-day price change of 5.70% and -33.17% over the past three months. PACB shares are trading -24.04% year to date (YTD), with the 12-month market performance down to -66.71% lower. […]
Analyst Expect Big Moves From Pacific Biosciences of California Inc (NASDAQ: PACB)
Currently, there are 273.86M common shares owned by the public and among those 243.51M shares have been available to trade. Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, […]
